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A fully integrated microfluidic device for point-of-care monitoring
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The simplicity and efficiency of point of care diagnostics have revolutionised patient care. Current methods for measuring
hypercoagulability often require trained technicians, large blood volumes, and result in long turnaround times. Standard
testing for hypercoagulable disorders is performed in the central laboratory using automated coagulation analysers.
However the trend is moving towards the development and implementation of point of care testing, as a result of the ever
increasing number of patients on antithrombotic therapy. We present a novel microfluidic device and assay for monitoring
the effect of two anticoagulants, unfractionated heparin (UFH) and low molecular weight heparin (LMWH). The assay is
based on the anti-Xa assay principle but uses fluorescence detection. Our device is a disposable laminate microfluidic strip,
fabricated from the cyclic polyolefin (COP), Zeonor®, which is extremely suitable for application to fluorescent device
platforms. We present data on the execution of the anti-Xa assay in this microfluidic format, demonstrating that the assay
can be used to measure both UFH and LMWH in human plasma samples from 0 to 1 U/mL, with a rapid result obtained
within 30-60 seconds.

Introduction
Antithrombotics are commonly administered for the treatment of
arterial and venous thromboembolism. Unfractionated heparins
and low molecular weight heparins are some of the traditional
antithrombotics used in the treatment and prevention of such
1
thromboembolic disorders. Low molecular weight heparin (LMWH)
has a more defined and predictable pharmacokinetic or
pharmacodynamic profile over unfractionated heparin (UFH) and it
2
also prefers FXa as a therapeutic target over thrombin.
Standard testing for coagulation disorders are usually based on the
principle of clotting and are carried out on automated
3
coagulometers. However with the advent of point of care (POC)
diagnostics, many of the standard clotting assays such as the
prothrombin time (PT) and activated partial thromboplastin time
(aPTT) have been translated into miniaturised POC devices.
Warfarin is commonly monitored using the HemoSense INRatio
monitor (HemoSense Inc., USA) which was developed for
determining the PT/INR of patients undergoing oral anticoagulation
treatment. Testing for anticoagulant therapy is very diverse with
numerous different tests available for assessing coagulation status,
however diagnostics based on the traditional testing principles are
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limited in terms of poor predictive value, poor quality and
4
accuracy. As a result there is a drive for the standardization of
current coagulation tests alongside a constant push for the
5
development of a global test of haemostasis.
6

The emergence of peptide substrates in the 1960s , had a knock-on
effect with the development of substrates specific for coagulation
proteins. As a result, the chromogenic anti-factor Xa (anti-FXa)
assay emerged as the new standard for monitoring LMWH therapy
in the central laboratory. The anti-FXa assay works on the principle
of the addition of exogenous FXa to a heparinised plasma sample,
which is incubated to allow the antithrombin (AT) in the sample to
form a complex with the excess FXa and heparin. The formation of
this complex allows AT to bind and inihibit thrombin and FXa more
strongly. The concentration of free FXa can then be measured using
a substrate that is selectively cleaved by the serine protease activity
7
of FXa. Once cleaved, the peptide substrate will release a
chromophore that can be detected colorimetrically.
As the field of microfluidics has advanced, POC technologies have
also developed and improved. Methods in microfabrication and
microfluidics have progressed so much in the last few years that
POC devices can be fabricated at low cost, they are easy to use,
8,9
portable and can generate rapid results. Silicon, glass, and
polymers are often the substrates of choice in the manufacture of
microfluidic devices as their chemical and physical properties are
well characterized. Silicon and glass can pose issues due to costly
fabrication processes, while polymers are low cost. Polymer-based
materials are highly versatile in that they suit many modes of
fabrication, are suitable for modification with surface chemistries
10
and are also highly reproducible. In the current study we have
used cyclic polyolefins (COPs) which belong to a class of polymers
employed due to their compatibility with biological materials, low
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autofluorescence, long shelf life and suitability for surface
11,12
modification amongst others.
Multilayer alignment fabrication
methodologies are commonly used to develop functional
13,14
microdevices
, as lamination of polymer layers offers greater
versatility and low cost. Zeonor® was chosen for this study, in
conjunction with PSA (pressure sensitive adhesive), as both are
suitable materials for simple fabrication and lamination
15
methodologies.
In our study we have developed a low cost, disposable, miniaturised
POC device. We have developed a three layered hybrid chip,
comprised of native hydrophobic Zeonor®, treated hydrophilic
16
Zeonor® and a PSA spacer that forms the channel. The assay is
incorporated onto the chip and works on the basis of the anti-Xa
principle outlined above. Using fluorescence as the method of
detection, the assay is capable of measuring therapeutic
concentrations of heparin in calibration plasmas from 0-1 U/mL and
in plasma samples from patients on heparin therapy.

Experimental
Reagents
Water (ACS reagent) and HEPES (minimum 99.5% titration) were
purchased from Sigma-Aldrich (Dublin, Ireland). Filtered HEPES was
prepared at a concentration of 0.01 mM (pH 7.4). A 100 mM filtered
stock solution of CaCl2 from Fluka BioChemika (Buchs, Switzerland)
was prepared from a 1 M CaCl2 solution.
The fluorogenic substrate methylsulfonyl-D-cyclohexylalanyl-glycylarginine-7-amino-4-methylcoumarin acetate (Pefafluor™ FXa) was
purchased from Pentapharm (Basel, Switzerland). It was
reconstituted in 1 ml of water having a stock concentration of 10
mM, aliquoted, covered with aluminum foil to protect from
exposure to light, and stored at -20 °C. Purified human FXa (serine
endopeptidase; code number: EC 3.4.21.6) was obtained from
HYPHEN BioMed (Neuville-Sur-Oise, France) and was reconstituted
in 500 µl of PCR grade water to give a stock concentration of 4400
nM. Unfractionated heparin (UFH) (sodium salt of heparin derived
from bovine intestinal mucosa, H0777) was sourced from SigmaAldrich (Dublin, Ireland). Low molecular weight heparin tinzaparin
(Innohep®) was obtained from Leo Pharma (Ballerup, Denmark).
Human pooled plasma was purchased from Helena Biosciences
Europe (Tyne and Wear, UK). Lyophilized plasma was reconstituted
in 1 ml of water and left to stabilise for at least 20 min at room
temperature prior to use.
Rolls of 188 µm thick cyclic polyolefin polymer (Zeonor®) were
purchased from IBIDI GmbH (Munich, Germany). ARcare® 92712 50
µm double sided pressure sensitive adhesive (PSA) and HY10coated Zeonor® was purchased from Adhesives Research (Limerick,
Ireland). Sheets of 188 µm Zeonor® was treated with a hydrophilic
coating from Hydromer Inc. (NJ, USA). Conjugate pads (CP) Type
8301 p/n SMCONO1 were sourced from Pall Europe Ltd.
(Portsmouth, England). Strip materials were cut using a Graphtec
Vinyl Cutter, Model CE5000-40-CRP from Graphtec GB Limited
(Wrexham, UK). Contact angle measurements were carried out
using an FTA 200 analyser from First Ten Angstroms, Inc. (Virginia,
USA).

All fluorescent measurements were carried out at 37°C using an
Olympus IX81 motorised fluorescent microscope sourced from
Olympus Europa GmbH (Hamburg, Germany) housed within an
incubation chamber with an attached Hamamatsu Orca ER digital
camera, Model C4742-80-12AG from Hamamatsu Photonics
(Hertfordshire, UK). Fluorescence was monitored according to the
following settings: magnification ×10; excitation at 342 nm and
emission at 440 nm; exposure time of 20 ms. All values of
fluorescence are reported as arbitrary fluorescence units (AU). All
measurements were analyzed using the CellˆR realtime imaging
software from Mason Technology (Dublin, Ireland) with subsequent
data exportation into Excel, SigmaPlot 8.0, and SPSS 22.0 for
analysis.
Microfluidic Assay and Device Development
Development of the microfluidic chip was divided into two stages.
In the first stage the fluorogenic substrate was deposited within the
microfluidic channel, while the FXa reagent was incubated
externally with plasma prior to its application on-chip. The results of
16
this study have been published previously. In the second stage of
development, the aim was to develop a fully integrated device with
all reagents incorporated on chip.

Integrated Strip Development
For the development of the integrated strip (Fig. 1), Zeonor® and
PSA were cut into multichannel sheets (13 strips) using the
Graphtec Vinyl Cutter (Fig. 2) from drawings designed using
AutoCAD® 2007. The Zeonor® lid was cut with thirteen elliptical
sample inlets of 4 mm diameter and rectangular outlets of 4 x 1.5
mm to allow air to escape from inside the channels. The PSA
channels were 50 mm long x 2 mm wide, with an additional area cut
across the channels at the inlet end, which measured 15 mm in
length by 5 mm width (Fig. 2). All 3 layers contain alignment marks
for easy assembly.
The CP was also cut to the same dimensions of 15 cm in length and
5 mm wide (Fig. 2). Each CP was dip coated in 200 µl of FXa and left
to dry for 2 hours in a desiccator at 19°C and 10% RH. Dip coating of
the conjugate pad took place in a “microdip tank vessel”. A scalpel
was used to cut the bulb and nozzle from a disposable pipette. The
trough created from the bulb is used to contain the FXa. The pipette
tip is placed over the needle, to provide a roller which attempts to
mimic a standard dip tank coating procedure, while avoiding metal
contamination from the needle. Both parts are disposed of after
use to avoid cross contamination with future batches.
The PSA layer was bonded to the Zeonor® lid layer using the
alignment marks and 2 µl of Pefafluor™ FXa fluorogenic substrate
was deposited with a pipette within each channel as four 0.5 µl
droplets onto the hydrophobic Zeonor® at a distance of 1.5 mm
from the outlet. Sheets were dried for 2 hours in a glass desiccator
with silica at 19°C and 10% RH. After drying, the CP was inserted
into the cut rectangular area on the PSA and bonded to the
hydrophilic Zeonor® base layer using pressure lamination.
Once the strip was assembled, 20 µl of re-calcified plasma (44 µl
heparinized plasma + 6 µl 100 mM CaCl2) was immediately applied
to the inlet of the assay strip. Plasma samples were spiked with
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pharmacologically relevant concentrations (0–1 U/mL) of UFH and
LMWH.

Results and Discussion
Strip materials characterisation and selection
Zeonor® was selected as the polymer of choice for microfluidic chip
development due to excellent optical characteristics for
fluorescence measurements. A range of surface modifications were
tested to render the hydrophobic Zeonor® surface hydrophilic. This
allowed for capillary fill of the microfluidic chip. A range of
materials were tested in terms of autofluorescence, capillary fill,
and contact angle (Table 1).
Table 1: Comparison of commercial hydrophilic surfaces in terms of
fluorescence, capillary fill, contact angle and the variability
associated with each measurement parameter (n=3).

Fig. 1. Schematic of the microfluidic chip highlighting the
hydrophobic Zeonor® lid layer (with inlet and outlet), the PSA
microchannel layer and the hydrophilic Zeonor base layer with
deposited reagents. The image to the right incorporates the
microdevice with a miniaturised detection system.

The HY10 treatment was not selected owing to its significant
contribution to background fluorescence (640.9 AU ± 2.3).
Fluorescence readings from the IBIDI Zeonor® and the Hydromer
Zeonor® were comparable, but the wettability of the IBIDI
treatment was poor by comparison with contact angles of 63.4º ±
2.8. As a result the Hydromer treated Zeonor® was selected with a
low autofluorescence (208.5 AU) in the UV spectrum, low contact
angles (17.5º ± 0.9) and capillary fill times of 20.3s ± 2.1.
A hybrid microfluidic device was developed by combining
unmodified Zeonor® with Hydromer-coated Zeonor®. This allowed
for deposition of reagent onto the hydrophobic film, while the
hydrophilic film served to induce capillary fill. The final assay
configuration was a three layer laminate chip comprising a 188 µm
thick hydrophilic base, a 50 µm PSA spacer with a channel, into
which the conjugate pad was inserted and a 188 µm thick
hydrophobic Zeonor® lid.

Fig. 2. Multichannel Zeonor® lid layer (A), PSA channel layer (B) and
CP containing the FXa reagent (C). The PSA layer containing the CP
in the inlet area, was sandwiched between the hydrophilic Zeonor®
lid layer and a hydrophobic Zeonor® base layer.

Patient Samples
A small preliminary study using patient samples was carried out.
Plasma samples from patients on UFH were kindly donated by
Tomas Lindahl based in the Linköping University Hospital, Sweden.
Ten plasma samples from patients on UFH were collected and
tested on our microfluidic device platform. Correlations were
performed with the assay standard, aPTT for UFH. Patient samples
were thawed at 37 °C in a water bath for 5 min and inverted for 5
min before testing on the anti-FXa microfluidic device. All
measurements were carried out in triplicate.

Assay Optimisation and Development
For the microfluidic chip developed, FXa and Pefafluor FXa™
fluorogenic substrate were titrated within the range of 560-760 nM
and 100-400 µM respectively. Fig. 3 (a) shows the typical
fluorescence profiles of a fixed concentration of 600nM FXa to
varying concentrations of Pefafluor™ FXa substrate and Fig. 3 (b)
shows the fluorescence responses at 60 s for 560-700 nM FXa and a
fixed concentration of 300 µM Pefafluor™ FXa in plasma at
concentrations of 0, 0.5 and 1 U/mL UFH. The optimal fluorogenic
substrate concentration was selected at a concentration that did
not limit the conversion of the substrate to product, which was
2
660nM returning an R of 0.98.
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Fig. 3. (a) Typical profiles of the anti-Xa assay at a fixed
concentration of 660 nM FXa and varying concentrations of
Pefafluor™ FXa. (b) Fluorescence responses at 30 s for a range of
FXa concentrations and a fixed concentration of 300 µM Pefafluor™
FXa at 0, 0.5, and 1 U/mL UFH (n=3).

Fig. 4: Linear regression analysis of fluorescent responses at 30, 60
and 90 seconds for (a) UFH and (b) LMWH. The fluorescence value
@ 30 seconds was selected as the most appropriate parameter for
measuring UFH, while the fluorescence value at 60 seconds was the
most appropriate measurement parameter for LMWH.

To select the optimal FXa concentration, the effect of heparin was
analyzed using regression analysis (Fig. 4). The optimal
concentration of FXa was selected that resulted in a wider signal
2
range than other concentrations, small error and an R value close
to 0.99. The optimal concentrations were selected as 300 µM
Pefafluor™ FXa substrate and 660 nM FXa for the final assay
development of the UFH assay (Fig. 4a). The FXa and Pefafluor™ FXa
fluorogenic substrate concentrations for the LMWH assay were
optimized as previously using regression analysis (Fig. 4b). Final
concentrations were selected as 650 nM FXa and 600 µM
Pefafluor™ FXa fluorogenic substrate.

The fluorescence responses of the optimized assay conditions were
tested over a range of UFH and LMWH concentration. The
concentration of heparin is inversely proportional to the rate of
fluorescence formation. As the concentration of drug increases, the
rate of fluorescence product formation decreases. Fig. 5 outlines
the dose response curves of human plasma spiked with UFH and
LMWH in the anti-Xa device. Various methods were investigated for
optimal data analysis and extraction, but the fluorescence value at
2
30 sec was most appropriate for UFH returning an R value of 0.98
(y = -4309.3x + 4061.1) (Pearson = 0.99). The fluorescence value at
60 sec was selected as the most appropriate value for LMWH giving
2
an R value of 0.97 (y = -3630x + 4053.8) (Pearson = 0.99). Assay
reproducibility was good with average CVs of <12% with one
exception at 0.25 U/mL for both the UFH and LMWH assays.
Variability at 0.25 U/mL was 35% for UFH and 19% for LMWH assay.
Statistical analysis returned significant differences in the variances
with the Levene’s test for the UFH assay (p = 0.007) and the LMWH
assay (p = 0.009), so one-way ANOVA could not be applied. When
equal variances were not assumed, the Tamhane test returned
significant differences, however UFH at a concentration of 0.25
U/mL resulted in significant error as a result of one outlier causing
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insignificant differences between 0.25 U/mL and all other
concentrations of UFH. The UFH assay had a statistically significant

Fig. 5. Dose response curve of human plasma spiked with UFH from
2
2
0 – 1 U/mL (R = 0.97) and LMWH from 0-1 U/mL (R = 0.99) in the
anti-Xa device (n=3).

range from 0 – 0.75 U/mL. The same pattern was also observed
with the LMWH assay where 0.25 U/mL did not appear significantly
different from 0 and 0.5 U/mL LMWH and 0.5 U/mL was not
significantly different from 0.75 U/mL. This again could be
attributed to the significant outlier encountered at 0.25 U/mL which
resulted in a CV of 19%. Variability of 12% was also observed at 0.75
U/mL. The LMWH assay had a statistically significant range from 0 –
1 U/mL.
Patient Analysis
To evaluate the integrated device, 10 plasma samples from patients
on UFH therapy were tested in the device. For these patients on
UFH therapy, the fluorescence responses from all patients were
converted into U/mL and correlated with the corresponding aPTT
value from the hospital laboratory. The correlation can be seen in
Fig. 6.

Fig. 6: UFH correlation: Anti-Xa device and hospital aPTT assay.
The fluorescence intensity value at 30 seconds was calculated for all
UFH patient samples. From the data presented in Fig. 6 it can be
seen that UFH generates a good correlation with a Pearson
coefficient of 0.88. The trend observed is that with increasing
fluorescence, the aPTT value decreases which is reflective of
decreasing heparin concentrations.
Quite a share of the POC market is occupied by coagulation
monitoring devices. Many of these POC diagnostics are based on
traditional methods and testing principles, such as clotting time
determined by PT, aPTT or ACT (activated clotting time). The
adaptation of many of these assays to POC devices was instigated
by the significant need for more rapid analysis of coagulation status
16
in emergency room settings. While these devices are commonly
used and there is a demand for them, there is certainly scope for
the development of novel devices that could improve upon
conventional testing methods.
The first move away from standard clot-based testing began in the
1960s with the development and introduction of peptide substrates
17,18
specific for coagulation proteins such as thrombin and plasmin.
Factor Xa was then identified as a significant protein in the
coagulation cascade, occupying a pivotal position that could be
19
targeted when monitoring anticoagulant therapy.
The
development of a FXa specific peptide substrate resulted in the
emergence of the anti-Xa colorimetric assay in 1976 which was used
6
to monitor heparin therapy. Central diagnostic laboratories refer to
the the anti-Xa assay as the ‘gold standard’ assay for measuring
heparin anticoagulant therapy. Despite its popularity, it has not yet
been translated into a POC device.
The work presented here focuses on the development of a POC
device for monitoring anticoagulant therapy in cardiac patients that
operates on the anti-Xa assay principle. Our initial aim was to
develop a simple disposable chip that incorporates the anti-Xa
assay. The simplicity of the chip is achieved through the mechanism
of capillary fill, so there is no integration of complex, sophisticated,
and costly instrumentation such as pumps or valves into the device.
The chip was fabricated from 188 µm Zeonor® which is easily
manipulated during manufacture on the Graphtec Vinyl Cutter.
Other microfluidic techniques such as laser ablation or hot
embossing can be costly to operate and often require skilled
operators, compared to cutting plotters which are user friendly and
low cost alternatives.
As aforementioned, COP was chosen as the substrate material for
this chip design as it offers additional advantages over polymers
such as polycarbonate (PC) and polyethylene terephthalate (PET) in
terms of its excellent optical clarity, high UV transmission, easy
modification of its surface and suitability for disposable POC
20–22
devices.
The concept of capillary force has long been used in lateral flow
tests which are the most commercially successful POC platforms
23
due to their simplicity. Native Zeonor® is highly hydrophobic
which is suitable for reagent deposition but it becomes problematic
when working with devices using capillary fill as it prevents flow. To
render the Zeonor® surface hydrophilic, three surface chemistries
were analyzed to modify the polymer. From the results obtained,
the Hydromer-modified Zeonor® with low water contact angles of
17.5° ± 0.9, produced the most reproducible capillary fill times of
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20.3 s ± 2.1. The device was based on a joint
hydrophilic/hydrophobic design to incorporate both the reagent
deposition and capillary fill components of the device. The method
of detection for this device is based on fluorescence, so Zeonor®
was selected, as it resulted in low background fluorescence at
wavelengths of 342 nm. Treatment with the HY10 coating resulted
in responses of 640.9 ± 2.3 AU, which were too high in terms of
background fluorescence.
The fully integrated device developed showed sensitivity in the
therapeutic ranges for UFH (0 – 0.75 U/mL) and LMWH (0 – 1
U/mL). Average CVs were <11%, despite high CVs at 0.25U/mL
which would be reduced with further device development.
Comparisons on levels of sensitivity and precision can only be
drawn with clot-based devices for heparin measurement currently
on the market, as an optical POC system for anticoagulant
monitoring is not currently available. Comparisons can be drawn
with the Hemochron® systems which are some of the most
commonly used POC coagulation devices on the market.
Hemochron® aPTT measurements report linearity with heparin up
to 1.5 U/mL, at intervals of 0.25 U/mL and CVs of <14%. Our system
is also outperforming other POC diagnostics in terms of volume and
turnaround times. The anti-Xa assay and device requires a small
sample volume of 20 µl and results processed within 30 or 60
seconds. This correlates with devices such as the CoaguCheck
(Roche Diagnostics, UK), yet significantly lower than the 50 µl
sample volume required for the Hemochron® systems.
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Conclusion
In terms of patient analysis, plasma samples from patients on UFH
were tested on the device and a Pearson correlation of 0.88 was
achieved by comparing fluorescence with clotting time. With low
heparin concentrations, fluorescence intensities are high and
clotting times are short. Here we present preliminary results of a
POC anti-Xa device but with further development, the fluorogenic
anti-Xa assay and device could prove successful for near-patient
monitoring of antithrombotics with the knock-on effect of
improving the health of patients on anticoagulant drugs.
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